Get the Daily Brief
Latest Biotech News
GSK inks up to $1B siRNA pact with Frontier Biotechnologies
GSK licensed two small interfering RNA (siRNA) assets from Frontier Biotechnologies in a deal that starts with a $40 million up‑front payment and can reach roughly $1 billion with milestones, the...
Gilead, Merck race on new daily HIV pills — weekly candidate also eyed
Gilead Sciences and Merck each reported data updates as they push forward novel daily HIV oral therapies while also exploring a longer‑acting weekly pill in partnership, the companies said. Both...
Pharma joins federated AI for ADMET: Apheris launches ADMET Network
Apheris announced the ADMET Network, a federated data initiative enabling pharmaceutical companies to collaboratively train ADMET (absorption, distribution, metabolism, excretion, toxicity)...
Samsung Biologics signs with CEPI to prep rapid vaccine surge capacity
Samsung Biologics will join the Coalition for Epidemic Preparedness Innovations (CEPI) Vaccine Manufacturing Facility Network to create a ‘ready‑to‑activate’ recombinant‑protein vaccine...
Gilead doubles down on cell therapy — Arcellx takeover seen as strategic play
Gilead moved to strengthen its cell therapy presence with the acquisition of Arcellx, a deal public reports put at roughly $7.8 billion, positioning the company to compete with established CAR‑T...
Pfizer secures global rights to Beam’s liver base‑editing candidate
Pfizer exercised an option to secure global licensing rights to Beam Therapeutics’ liver‑targeted gene‑editing candidate after Beam’s strategic shift away from in‑house gene therapy...
Cell‑free CSF proteomics yields 22‑protein MS marker panel in Cell
An international proteomics team led by Matthias Mann and Jakob Bader identified 22 cerebrospinal‑fluid protein markers for multiple sclerosis (MS) using high‑throughput liquid...
Proteomimetic polymers degrade MYC and KRAS — new route to 'undruggable' targets
Northwestern University researchers reported HYDRACs—heterobifunctional proteomimetic polymers (protein‑like polymers)—that bind oncogenic proteins MYC and KRAS and recruit cellular degradation...
Gilead buys Arcellx: $7.8B deal to own anito‑cel
Gilead Sciences agreed to acquire Arcellx in a $7.8 billion transaction that brings the BCMA‑directed CAR‑T therapy anito‑cel fully under Gilead’s control. The deal consolidates development and...
Beam targets PKU with base editing – Pfizer secures liver rights
Beam Therapeutics launched BEAM‑304, a liver‑targeted base‑editing program designed to correct common PAH mutations that cause phenylketonuria (PKU), and signaled intent to file an IND in 2026....
Novo slashes GLP‑1 prices: $675 list, touts near‑20% triple‑G data
Novo Nordisk announced a dramatic cut to list prices for its GLP‑1 medicines, moving Wegovy and Ozempic to a $675 monthly list price beginning in 2027, aimed at patients with high deductibles and...
GSK shells out $950M: buys 35Pharma to add HS235 for pulmonary hypertension
GlaxoSmithKline agreed to acquire Canadian biotech 35Pharma for $950 million in cash to obtain HS235, a protein‑based investigational therapy targeting activin receptor signalling with potential...
ARPA‑H awards $38M: UTSA’s Barshop named national aging hub
The Sam and Ann Barshop Institute for Longevity and Aging Studies at UT San Antonio secured up to $38 million from ARPA‑H to establish a multi‑year program focused on aging and healthy longevity....
FDA pivots: single pivotal trial plus evidence now acceptable
The U.S. Food and Drug Administration announced a policy shift that allows approvals on the basis of one well‑controlled pivotal trial supplemented by confirmatory evidence, replacing the...
FDA halts MacroGenics trial after patient death – enrollment frozen
The FDA placed a partial clinical hold on MacroGenics’ Phase II lorigerlimab study in gynecologic cancers following one patient death and multiple life‑threatening adverse events, ordering a stop...
BreezeBio raises $60M: polymer nanoparticles to carry mRNA diabetes program
BreezeBio closed a $60 million financing to advance its polymer nanoparticle delivery platform and initiate clinical testing of its lead mRNA program for diabetes. The company, which refocused...
PacBio, DNAstack launch federated HiFi data hub for rare disease
Pacific Biosciences and DNAstack launched a secure, federated environment to share HiFi whole‑genome sequencing data and metadata across the HiFi Solves Global Consortium, aimed at accelerating...
FDA approves Loargys for ARG1‑D: accelerated nod for ultrarare disorder
The FDA granted accelerated approval to Immedica Pharma’s Loargys (pegzilarginase) to treat arginase‑1 deficiency (ARG1‑D) in patients aged two and older, addressing a disorder that affects...
Gilead buys Arcellx for $7.8B—takes full control of anito‑cel
Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure full ownership of anito‑cel, the BCMA‑directed CAR‑T therapy now under FDA review. The deal converts an existing collaboration...
Novo Nordisk inks Vivtex pact—slashes GLP‑1 list prices
Novo Nordisk signed a collaboration with Vivtex to license oral drug‑delivery technology aimed at converting injectable biologics into pills, with deal economics worth up to $2.1 billion in...